U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C26H29F2N7
Molecular Weight 477.5522
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALMITRINE

SMILES

FC1=CC=C(C=C1)C(N2CCN(CC2)C3=NC(NCC=C)=NC(NCC=C)=N3)C4=CC=C(F)C=C4

InChI

InChIKey=OBDOVFRMEYHSQB-UHFFFAOYSA-N
InChI=1S/C26H29F2N7/c1-3-13-29-24-31-25(30-14-4-2)33-26(32-24)35-17-15-34(16-18-35)23(19-5-9-21(27)10-6-19)20-7-11-22(28)12-8-20/h3-12,23H,1-2,13-18H2,(H2,29,30,31,32,33)

HIDE SMILES / InChI

Molecular Formula C26H29F2N7
Molecular Weight 477.5522
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Almitrine, a selective pulmonary vasoconstrictor and a respiratory stimulant that enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. The drug increases arterial oxygen tension while decreasing arterial carbon dioxide tension in patients with chronic obstructive pulmonary disease. In combination with raubasine, it used under the brand, name Duxil for the treatment of age-related cerebral disorders and functional rehabilitation after stroke. In addition, Duxil has been considered as an alternative treatment for dementia, but because of the low methodological quality of included trials and the small number of trials, the obtained data did not provide sufficient evidence to support the routine use of this drug for the disease.

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

PubMed

Substance Class Chemical
Record UNII
9A1222NBG4
Record Status Validated (UNII)
Record Version